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Secretoglobin and Transferrin Expression in Bronchoalveolar Lavage
Fluid of Horses with Chronic Respiratory Disease
M. Miskovic Feutz, L.L. Couetil, C.P. Riley, X. Zhang, J. Adamec, and R.E. Raskin
Background: Lower expression of secretoglobin and transferrin has been found in the bronchoalveolar lavage ﬂuid
(BALF) of a small number of horses with experimentally induced signs of recurrent airway obstruction (RAO) compared to
healthy controls.
Hypothesis/Objectives: Secretoglobin and transferrin BALF expression will be similarly decreased in horses with naturally
occurring clinical signs of RAO and in horses with experimentally induced clinical signs of RAO as compared to healthy controls and intermediate in horses with inﬂammatory airway disease (IAD).
Animals: Recurrent airway obstruction-aﬀected and control horses were subjected to an experimental hay exposure trial
to induce signs of RAO. Client-owned horses with a presumptive diagnosis of RAO and controls from the same stable environments were recruited.
Methods: Pulmonary function and BALF were evaluated from control and RAO-aﬀected research horses during an
experimental hay exposure trial (n = 5 in each group) and from client-owned horses (RAO-aﬀected horses, n = 17; IAD-affected horses, n = 19; healthy controls, n = 5). The concentrations of secretoglobin and transferrin in BALF were assessed
using Western blots.
Results: Naturally occurring and experimentally induced RAO horses had similar decreases in BALF transferrin expression, but secretoglobin expression was most decreased in naturally occurring RAO. Secretoglobin and transferrin expression
were both lower in BALF of RAO-aﬀected horses than in IAD-aﬀected and control horses.
Conclusions and Clinical Importance: Secretoglobin and transferrin expression is decreased in BALF of RAO-aﬀected
horses after both experimental and natural exposure. Secretoglobin and transferrin likely play clinically relevant roles in the
pathophysiology of RAO, and may thus be used as biomarkers of the disease.
Key words: Heaves; Inﬂammatory airway disease; Recurrent airway obstruction; Western blot.

ecurrent airway obstruction (RAO) is a chronic
respiratory disease in horses characterized by airway inﬂammation, obstruction, and hyperresponsiveness. Clinical signs of RAO include increased resting
respiratory eﬀort, cough, and exercise intolerance.1
Recurrent airway obstruction has an environmental
allergy component as well as a genetic predisposition in
certain horses.1,2 Because of the wide genetic variation
among breeds and individual horses and the complex
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pathophysiology of allergic diseases, it has been diﬃcult
to deﬁnitively elucidate the mechanisms of RAO.
Horses with IAD exhibit milder clinical signs including
coughing and poor performance with normal respiratory eﬀort at rest.3
Pulmonary airways are the primary disease site in
RAO, and bronchoalveolar lavage ﬂuid (BALF) has
been extensively studied in RAO-aﬀected horses to
determine the pathophysiologic mechanisms that contribute to RAO. Over 500 proteins have been identiﬁed
in BALF in healthy horses,4 and the use of traditional
methods for investigating changes in protein concentrations in the face of disease exacerbation can be challenging because these techniques require preselection of
a very small number of potential mediators.
In a previous study utilizing proteomic techniques,
we identiﬁed 370 peptides corresponding to 250 unique
proteins in RAO-aﬀected and control horses after an
experimental antigen exposure trial.5 Eighteen identiﬁed
peptides showed diﬀerential expression between the
RAO-aﬀected and control horses. We validated the
expression levels of 2 proteins, secretoglobin and transferrin, using Western blots.
In this study, we used Western blots to evaluate
the expression levels of secretoglobin and transferrin
in a population of horses with naturally occurring

Secretoglobin and Transferrin in RAO

clinical signs of RAO and environmentally matched
controls. Our primary hypothesis was that BALF
expression of secretoglobin and transferrin would be
similar in naturally occurring and experimentally
induced RAO and would be lower than in control
horses.

Materials and Methods
Animals
All procedures were approved by the Purdue University Animal Care and Use Committee. Five horses aﬀected with RAO
(Purdue-owned RAO-aﬀected) and 5 control horses (Purdueowned controls) were evaluated before and after experimental
exposure to moldy hay. The horses used in this study were the
same horses used in the exposure trial reported previously.5 In
the initial study,5 3 of the horses previously diagnosed with
RAO did not respond to the exposure trial. These horses were
excluded from the analysis for the study reported here. We
chose to include only the 5 control horses that were paired with
the RAO-aﬀected horses (stalled adjacent and tested on the
same days) that had responded to the moldy hay challenge.
Forty-one horses were referred to the Purdue University College
of Veterinary Medicine after a mailed solicitation. Twenty client-owned horses had a history of chronic respiratory disease
and were referred with a presumptive diagnosis of RAO. The
21 client-owned companion horses were from the same farms
and managed under the same conditions as the RAO-aﬀected
horses, but had no history or clinical signs of respiratory diseases. All horses were fed some type of hay during the year.
One horse that had been diagnosed previously with RAO was
fed hay cubes, 1 was fed haylage, and 1 was only fed hay during the winter months. A variety of treatment options had been
pursued for the horses with a presumptive diagnosis of RAO.
None of these horses had been treated in the 2 weeks before
this study. Detailed treatment information was not available for
all horses. For all other horses, hay was fed both inside the
barn and outside at pasture. More than half the horses (22/41)
were fed hay from large round bales. Most horses were stabled
for at least part of the day throughout the year (15/41 were
stabled for more than 6 hours/d; 12/41 were never stabled).
Horses were bedded on straw, wood shavings, or sawdust
when they were stalled. All client-owned horses underwent the
same pulmonary function testing and BALF collection as the
Purdue-owned horses but were not subjected to a hay exposure
trial.
In order to be considered a control horse, the horse must
have had no history of chronic respiratory disease, no evidence
of airway obstruction (maximum change in transpulmonary
pressure [ΔPLmax] < 10 cm H2O) and <10% neutrophils, <1%
eosinophils, and <2% mast cells on BALF cytology. Horses
aﬀected with RAO were diagnosed based on a history of
chronic respiratory disease (>3 months), increased respiratory
eﬀorts upon presentation, evidence of airway obstruction
(ΔPLmax > 10 cm H2O), and >10% neutrophils on BALF cytology. Inﬂammatory airway disease (IAD) was diagnosed based
on normal pulmonary function testing (ΔPLmax < 10 cm H2O)
and >10% neutrophils, >1% eosinophils, or >2% mast cells on
BALF cytology; history of client-reported respiratory disease
was variable. After testing, 17 horses were determined to have
RAO, 5 horses were healthy controls, and the remaining 19
horses had IAD. Some of the horses that were presented with a
presumptive diagnosis of RAO were actually diagnosed with
IAD. Similarly, many of the horses presented as healthy controls were diagnosed with IAD.
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Respiratory Evaluation
Testing was performed according to standard laboratory procedures as previously described.6 A physical examination was
performed on each horse and a clinical score (range, 0–21) was
calculated based on respiratory rate and eﬀort, thoracic auscultation ﬁndings, cough, and nasal discharge.7 The horses were then
restrained in stocks without sedation and ﬁtted with an esophageal
balloon catheter, a face mask, and a pneumotachometer as
described previously.6 Breath-by-breath measurement of esophageal and mask pressures and airﬂow were performed. Data analysis of 10 representative breaths yielded mean total pulmonary
resistance, dynamic compliance, and ΔPLmax. After pulmonary
function testing, horses were sedated with butorphanol and detomidine in preparation for BAL. Bronchoalveolar lavage was
performed using a 2-m long video-endoscope and 250-mL bolus of
sterile saline solution as described previously.8 The BALF was
placed on ice and processed within 20 minutes of collection.

BALF Analysis
An aliquot of BALF was prepared for cytological examination by cytocentrifugation and stained with modiﬁed Wright’s
stain. Total nucleated cell counts were determined by use of a
hemacytometer. Diﬀerential cell counts were determined by the
examination of 200 leukocytes per slide. The clinical pathologist
evaluating the BALF cytology was blinded to each horse’s
group identity. The remainder of the BALF was ﬁltered through
sterile gauze and centrifuged at 300 9 g for 10 minutes. Protein
concentration in the BALF of each horse was measured using a
BCA assay,a according to the manufacturer’s protocol. The
supernatant was stored at 80°C in 1 mL aliquots until further
analysis.

Western Blot
Secretoglobin and transferrin expression in BALF supernatant
was quantiﬁed by Western blot in the Purdue-owned RAO-aﬀected
and control horses before and after the experimental exposure trial
(n = 5 in each group), client-owned RAO-aﬀected horses with naturally occurring disease (n = 17), client-owned healthy controls
(n = 5), and client-owned IAD-aﬀected horses (n = 19). Western
blots were performed according to the manufacturer’s recommendationsb to conﬁrm the identity of secretoglobin and transferrin in
all BALF samples with 2 lg of protein from each sample. In the
Western blot for secretoglobin, the positive control protein was
equine recombinant secretoglobinc with monoclonal rabbit antihorse secretoglobin antiserum as the primary antibodyc (dilution
1 : 1000) and horseradish peroxidase-conjugated goat antirabbit
IgG as the secondary antibodyd (dilution 1 : 2000). In the Western
blot for transferrin, the positive control protein was human apotransferrine with polyclonal sheep antihorse transferrin as the
primary antibodyf (dilution 1 : 10,000) and horseradish peroxidase-conjugated donkey antisheep IgG (H + L) as the secondary
antibodyg (dilution 1 : 100,000). ImageJ softwareh was used to
quantify the density of the bands from the protein of interest in
each Western blot.

Statistical Analysis
Statistical analysis was performed with Statistica.f,i A factorial
ANOVA was used to evaluate pulmonary function, BALF, and
Western blot data among the Purdue-owned horses before and
after the experimental exposure trial. The Fisher’s least signiﬁcant
diﬀerences (LSD) test was used for posthoc testing.
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For the client-owned horses, the Mann–Whitney U-test was
used to perform pairwise comparisons evaluating pulmonary function, BALF, and Western blot data between RAO-aﬀected and
control horses from the same environment (n = 4 in each group)
and between RAO-aﬀected and IAD-aﬀected horses from the same
environment (n = 12 in each group). The Kruskal–Wallis ANOVA
was used to evaluate diﬀerences among all 3 groups of horses
(RAO-aﬀected n = 17, IAD-aﬀected n = 19, control n = 5). The
multiple comparisons test was used for posthoc testing.
The Mann–Whitney U-test was used to compare pulmonary
function, BALF, and Western blot data between the Purdueowned control horses at baseline (n = 5) and the client-owned control horses (n = 5) and between the Purdue-owned RAO-aﬀected
horses at exposure (n = 5) and the client-owned RAO-aﬀected
horses (n = 17) to assess the validity of the experimental model as
a comparison population. The groups were found to be comparable, and thus were pooled together for further analysis of the Western blot data.
The relationship between the density of secretoglobin and transferrin expression in BALF and pulmonary function testing variables and BALF cytology variables was evaluated using the
Spearman rank correlation test. All available pulmonary function,
BALF, and Western blot data were used in this analysis (i.e., data
from all Purdue-owned and client-owned horses). In all statistical
analyses, P < .05 was considered statistically signiﬁcant. Data are
presented as median (range).

percentage of lymphocytes in BALF at exposure. There
were no changes in the pulmonary function measurements of the control horses between baseline and
exposure (Table 1).

Respiratory Evaluation, Client-Owned Horses
There was no signiﬁcant diﬀerence in age or body
weight among the 3 groups of client-owned horses. The
RAO-aﬀected horses showed evidence of airway
obstruction and had a higher clinical score than did the
control and IAD-aﬀected horses (Table 2). The RAOaﬀected horses had a decreased percentage of macrophages and an increased percentage of neutrophils in
BALF compared to the control and IAD-aﬀected
horses. The IAD-aﬀected horses had an increased percentage of eosinophils in BALF compared to the RAOaﬀected horses.
The RAO-aﬀected horses had a higher clinical score,
evidence of airway obstruction, and airway neutrophilia. The IAD-aﬀected horses had eosinophilic, mast cell,
or neutrophilic airway inﬂammation, but no detectable
airway obstruction (Table 3).

Comparison of Purdue-Owned to Client-Owned
Horses

Results
Respiratory Evaluation, Purdue-Owned Horses
The control horses were younger (16 years [10–19])
than the RAO-aﬀected horses (21 years [17–26],
P = .012). There were no diﬀerences in the weights of
the horses. At baseline, there was no signiﬁcant diﬀerence in the pulmonary function or BAL parameters
between RAO-aﬀected and control horses. After exposure, the RAO-aﬀected horses had evidence of airway
obstruction and neutrophilic airway inﬂammation
(Table 1).
The control horses also had some diﬀerences between
baseline and exposure, namely an increase in the percentage of neutrophils in BALF and a decrease in the

We compared the Purdue-owned control horses at
baseline to the client-owned control horses and the
Purdue-owned RAO horses at exposure to the clientowned RAO horses to assess the validity of using the
experimentally induced disease as a model for the naturally occurring disease. We chose to use the Purdueowned horses at baseline because this location was
their natural environment. The exposure status of these
horses was after a moldy hay challenge. Although the
client-owned horses had been in an environment that
elicited clinical signs in RAO-aﬀected horses after
long-term exposure, we did not feel that this environment was comparable to the moldy hay challenge that

Table 1. Summary statistics concerning Purdue-owned RAO and control horses before and after experimental exposure to moldy hay. Data displayed as median (range).
Baseline
Controls (n = 5)
Clinical score
ΔPmax (cm H2O)
Cdyn (L/cm H2O)
Rl (cm H2O/l/s)
% BALF macrophages
% BALF neutrophils
% BALF lymphocytes
% BALF eosinophils
% BALF mast cells

1
6.2
3.7
0.4
62
4
27
0
3

(1–2)
(3.1–10.0)
(1.7–6.7)
(0.2–0.9)
(52–69)
(3–4)
(22–40)
(0–0)
(0–5)

Hay exposure
RAO (n = 5)
2
5.1
4.7
0.4
48
18
27
0
2

(1–4)
(1.8–13.0)
(1.0–7.7)
(0.2–1.2)
(22–65)
(3–53)
(10–43)
(0–3)
(1–6)

Controls (n = 5)
3
5.9
3.4
0.5
55
24
13
0
2

(1–3)
(5.4–8.5)
(1.3–4.4)
(0.4–0.7)
(49–69)
(18–31)*
(10–19)*
(0–1)
(0–6)

RAO (n = 5)
11
26.6
0.6
1.8
32
49
11
0
1

(7–13)†,‡
(21.8–34.8)†,‡
(0.4–1.0)‡
(1.5–2.1)†,‡
(12–48)†
(31–70)†,‡
(7–24)‡
(0–5)
(0–6)

ΔPmax, maximum transpulmonary pressure change; Cdyn, lung dynamic compliance; Rl, lung resistance; BALF, bronchoalveolar lavage
ﬂuid; AUC, area under the curve; RAO, recurrent airway obstruction.
†
Signiﬁcantly diﬀerent from controls at exposure (P < .05).
‡
Signiﬁcantly diﬀerent from RAO at baseline (P < .05).
*Signiﬁcantly diﬀerent from controls at baseline (P < .05).
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Table 2. Summary statistics concerning client-owned
RAO, IAD and control horses. Data displayed as median (range).
Controls
(n = 5)
Clinical score
ΔPmax (cm H2O)
Cdyn (l/cm H2O)
Rl (cm H2O/l/s)
% BALF
macrophages
% BALF
neutrophils
% BALF
lymphocytes
% BALF
eosinophils
% BALF
mast cells

2
5.4
2.8
0.4
59

(0–5)
(4.1–6.4)
(0.7–6.9)
(0.2–0.6)
(43–63)

ranges for Purdue-owned horses were within the data
ranges for client-owned horses.

Western Blots
RAO (n = 17)
10
16.3
0.8
1.5
19

(4–17)‡
(10.5–66.6)‡
(0.2–7.6)
(0.7–5.6)‡
(2–53)‡

IAD (n = 19)
4
6.4
2.8
0.4
50

(0–9)
(3.2–9.2)
(1.4–7.5)
(0.3–0.6)
(11–77)

44 (12–95)‡

11 (1–60)

35 (29–50)

21 (2–70)

24 (9–55)

0 (0–0)

0 (0–0)†

0 (0–4)

1 (0–2)

0 (0–4)

4 (2–6)
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3.0 (0–9)

RAO, recurrent airway obstruction; IAD, inﬂammatory airway
disease; BALF, bronchoalveolar lavage ﬂuid.
†
Signiﬁcantly diﬀerent from IAD-aﬀected horses (P < .05).
‡
signiﬁcantly diﬀerent from controls and IAD-aﬀected horses
(P < .05).

the Purdue-owned control horses experienced before
evaluation. The Purdue-owned RAO-aﬀected horses
were older (21 years [17–26]) than the client-owned
RAO horses (15 years [8–21]; P = .0064). In the comparison between the 2 control groups (n = 5 in each
group), the client-owned horses had slightly higher respiratory rates (14 breaths/min [12–19]) than the Purdue-owned horses (9 breaths/min [6–11]; P = .021).
This diﬀerence was attributed to the familiarity of the
Purdue-owned horses with the laboratory environment.
Otherwise, there were no signiﬁcant diﬀerences in pulmonary function measurements or in the cell percentages in BALF between the 2 groups. In addition, the
average clinical, functional, and cytological variables of
RAO horses were similar in magnitude, and data

In the Purdue-owned horses, the RAO-aﬀected horses
at exposure had lower expression of transferrin than at
baseline (P < .001), and lower expression of transferrin
than the control horses at exposure (P = .0011; Fig 1).
The client-owned RAO-aﬀected horses had lower
expression of transferrin than did the client-owned
IAD-aﬀected horses (P = .030), but no signiﬁcant diﬀerence was observed from the client-owned control horses
(Fig 2). The client-owned RAO-aﬀected horses also had
a lower expression of secretoglobin than did the clientowned IAD-aﬀected horses (P < .001) and the clientowned control horses (P = .0037; Figs 1 and 2). When
compared with the IAD-aﬀected horses from the same
environments, the client-owned RAO-aﬀected horses
had no diﬀerence in transferrin expression, but a lower
secretoglobin expression (P = .0014; Table 3).
When comparing the Purdue-owned horses to the client-owned horses, we found no diﬀerences in transferrin
or secretoglobin expression in the control groups. The
Purdue-owned RAO-aﬀected horses had higher secretoglobin expression than did the client-owned RAO-affected horses (P = .017; Fig 1), but no diﬀerence in
transferrin expression.
The expression of secretoglobin and transferrin in
BALF were both negatively correlated with clinical
score, indicators of airway obstruction, and percentage
of neutrophils in the BALF (Table 4). The expression
of transferrin also was positively correlated with the
percentage of mast cells in BALF (Table 4).

Discussion
In this study, we evaluated 2 populations of RAO-affected horses with environmentally matched pairs:
RAO-aﬀected horses with clinical signs exacerbated by

Table 3. Comparison of respiratory parameters between groups of client-owned horses originating from the same
stable environment (12 RAO/IAD pairs and 4 RAO/control pairs).
RAO
N = 12
Clinical score
ΔPmax (cm H2O)
Cdyn (L/cm H2O)
Rl (cm H2O/l/s)
% BALF macrophages
% BALF neutrophils
% BALF lymphocytes
% BALF eosinophils
% BALF mast cells
Secretoglobin (relative density)
Transferrin (relative density)

12
16.3
0.8
1.2
31
44
18
0.0
0
874
4136

(6–17)*
(11.3–66.6)*
(0.4–7.6)
(0.7–5.6)*
(2–53)*
(12–93)*
(2–60)
(0.0–0.0)*
(0–3)*
(299–4307)*
(167–7075)

IAD
N = 12
3
6.7
2.4
0.4
54
12
22
0.3
3
8181
5882

(0–9)
(4.3–9.0)
(1.5–3.9)
(0.3–0.6)
(11–73)
(2–48)
(9–46)
(0.0–4.5)
(0–5)
(1210–10892)
(2970–7720)

RAO
N=4
8
22.5
0.6
2.2
16
27
43
0.0
3
696
4223

(4–13)†
(18.9–26.0)
(0.2–0.9)
(1.4–3.1)
(13–23)*
(5–53)†
(24–70)
(0.0–19.0)
(0–11)
(140–1120)*
(1142–5693)

Controls
N=4
2
6.0
2.4
0.4
57
4
39
0
1
6506
7005

(0–5)
(4.1–6.4)
(0.7–3.17)
(0.2–0.6)
(43–61)
(2–6)
(31–50)
(0–0)
(0–2)
(5121–10146)
(1875–7342)

RAO, recurrent airway obstruction; IAD, inﬂammatory airway disease; BALF, bronchoalveolar lavage ﬂuid.
*Parameter signiﬁcantly diﬀerent between the RAO horses and the other group of horses originating from the same stable environment
(P < .05).
†
Trend toward a diﬀerence between the RAO horses and the other group of horses originating from the same stable environment
(P = .057).
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P = 0.0037 P < 0.001

9000

Relative secretoglobin density

8000

P = 0.017
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PU RAO baseline
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PU RAO exposure
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Controls

Client RAO

Client IAD

B
9000

P < 0.001
8000

P = 0.001

P = 0.03

Relative transferrin density

7000
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5000
4000
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1000
0
PU Controls baseline

PU RAO baseline

PU Controls exposure

PU RAO exposure

Client
Controls

Client RAO

Client IAD

Fig 1. Relative band density of Western blots performed using BALF samples probed with monoclonal antibodies against (A) Transferrin
and (B) Secretoglobin. Samples were collected from Purdue-owned (PU) control and RAO horses at baseline and after exposure to moldy
hay and from client-owned (Client) control, RAO, and IAD horses. BALF, bronchoalveolar lavage ﬂuid; RAO, recurrent airway obstruction; IAD, inﬂammatory airway disease.

an experimental exposure to moldy hay and companion
control horses, and RAO-aﬀected horses with clinical
signs exacerbated by natural environmental exposure
and companion control and IAD-aﬀected horses. When
comparing the 2 groups of RAO-aﬀected and control
horses, we found negligible diﬀerences between the variables assessed. Presumably, the types and amounts of
allergens to which the 2 groups of RAO-aﬀected horses
were exposed and the length of exposure varied, however, the horses showed a similar degree of small airway
obstruction and pulmonary inﬂammation. With these
similarities, we can expect similar diﬀerences in the
protein composition of the BALF.
From the selection of peptides that showed diﬀerential expression between the RAO-aﬀected and control
horses in a previous study,5 we chose to validate the

identity and expression levels of secretoglobin and
transferrin. Both proteins have been implicated in the
pathogenesis of respiratory diseases in humans,9–12 and
secretoglobin has been implicated in the pathogenesis of
RAO in horses.13,14 We were also able to obtain
equine-speciﬁc reagents for Western blots for both
proteins.
Secretoglobin expression was signiﬁcantly decreased
in the RAO-aﬀected horses compared to that in the
control horses and IAD-aﬀected horses. This ﬁnding is
in agreement with previous studies evaluating secretoglobin in RAO.13 Our previous study showed no signiﬁcant diﬀerence in the experimental exposure model
between RAO-aﬀected and control horses after both
groups of horses were subjected to the experimental
antigen exposure.5 We suspect this ﬁnding was a result
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STD

A

RAO1 RAO2 RAO3 RAO4 RAO5 RAO6 CTL1

CTL2
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CTL3

CCSP

BLK

B
TF2 TF1.5

TF1

BLK CTL1 CTL2

CTL3 CTL4 CTL5 CTL6 RAO1 RAO2 RAO3 RAO4 RAO5

Fig 2. Western blots performed using BALF samples collected from client-owned control horses (CTL) and horses with recurrent airway
obstruction (RAO). (A) Secretoglobin, (B) Transferrin. BLK: blank; STD: protein standards. TF2: 2.0 lg of transferrin control protein
(human apo-transferrin). BALF, bronchoalveolar lavage ﬂuid.

Table 4. Correlation coeﬃcients (r) between secretoglobin and transferrin expression and various respiratory parameters (clinical score, pulmonary function,
BALF cytology) collected from horses with chronic respiratory disease and controls (n = 60).
Secretoglobin
r
Clinical score
ΔPmax (cm H2O)
Cdyn (l/cm H2O)
Rl (cm H2O/l/s)
% BALF macrophages
% BALF neutrophils
% BALF lymphocytes
% BALF eosinophils
% BALF mast cells

0.57
0.50
0.46
0.50
0.51
0.33
0.087
0.068
0.033

P value
<.001
<.001
.0015
<.001
<.001
.0093
.51
.61
.80

Transferrin
r
0.48
0.62
0.19
0.61
0.41
0.36
0.025
0.083
0.32

P value
<.001
<.001
.20
<.001
.0010
.0051
.85
.53
.014

BALF, bronchoalveolar lavage ﬂuid.

of small sample size, relatively short duration of
antigenic exposure, and individual variation in secretoglobin concentrations. In addition, the control horses
in the experimental exposure model did show some
degree of airway inﬂammation after exposure to a dusty
environment. In this larger study, the lower concentrations of secretoglobin in equine BALF in naturally
occurring RAO compared to control horses without
pulmonary inﬂammation strongly suggest that prolonged exposure to environmental antigens is associated
with depletion of secretoglobin as hypothesized by
others.13 An additional ﬁnding was that secretoglobin
expression was signiﬁcantly higher in horses with IAD
compared to those with RAO. Horses with IAD may
be diﬃcult to diﬀerentiate from those with RAO based
on clinical signs and BALF cytology alone. Pulmonary
function testing is considered the reference standard,
but is only available at few referral centers.6 Because of
the correlation between secretoglobin in BALF and

indicators of airway disease severity, this protein may
prove to be a valuable biomarker to help diﬀerentiate
mild (IAD) from severe (RAO) chronic airway disease.
Secretoglobin is an anti-inﬂammatory protein that
inactivates phospholipase A2, decreases proinﬂammatory cytokine production, alters phagocyte function,
and may decrease the inﬂammatory response to endotoxin.11 The pathophysiologic mechanism of secretoglobin in RAO of horses and asthma of humans is
still unclear, but it does appear to play a role in both
diseases. Secretoglobin is decreased in the serum of
humans with asthma.9 Secretoglobin-positive airway
epithelial cells are fewer in number in people with
asthma and in horses with RAO.13,15 Based on the studies in secretoglobin-deﬁcient mice, secretoglobin seems
to be necessary for adequate viral clearance and attenuation of the pulmonary inﬂammatory response to viral
infection and allergen exposure.16,17
Although most mammals have only 1 gene that
encodes the secretoglobin protein, horses have 3 such
genes.18 One of these genes is thought to be a pseudogene, whereas the other 2 code for functional, but different, secretoglobin proteins. Horses with RAO
showing clinical signs do have a diﬀerent expression of
the 2 secretoglobin variants than do control horses, and
it seems to be associated with diﬀerential eﬀects on neutrophil function.19 This relationship has not yet been
evaluated in horses with IAD. However, the diﬀerence
in BALF secretoglobin expression between RAO-affected and IAD-aﬀected horses implies that these
diseases may have diﬀerent pathophysiology or represent variable severity of the same disease process.
The expression of transferrin in BALF was signiﬁcantly lower in RAO-aﬀected horses compared to IADaﬀected horses and control horses. Because transferrin
is a negative acute phase protein, a decrease in the face
of inﬂammation is expected with both RAO and IAD.
The relationship between transferrin and pulmonary
inﬂammation is not as clear as that of secretoglobin. In
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people with acute exposure to swine dust, BALF transferrin concentration actually increases within 24 hours
of exposure.12 This previous study hypothesized that
the acute increase in BALF transferrin is caused by
plasma exudation into the airways in the face of acute
inﬂammation. Patients with acute respiratory distress
and on a mechanical ventilator have lower BALF transferrin concentrations than do healthy controls, but
patients with chronic obstructive pulmonary disease and
on a mechanical ventilator have higher BALF transferrin concentrations than do healthy controls.20 Patients
in status asthmaticus have higher sputum transferrin
concentrations than do patients with chronic bronchitis
(healthy control subjects were not evaluated in this
study).21 Serum and BALF transferrin concentrations
are higher in people with methylene diisocyanate-induced occupational asthma, compared to asymptomatic
people exposed to the same environment (exposure of
4–5 years).22 Because transferrin is a predominant
plasma protein, it is likely that increases in BALF or
sputum transferrin concentrations reﬂect plasma exudation into the lungs, and it may be diﬃcult to separate
pulmonary transferrin production from systemic
transferrin production without serial measurements of
transferrin concentration in both BALF and serum.
Another option to assess pulmonary transferrin production, rather than performing serial measurements, could
be to correct for BALF dilution using inulin as an
exogenous marker or urea as an endogenous marker of
pulmonary epithelial lining ﬂuid concentration in the
collected BALF.23
The timing of sample collection should be noted
when evaluating transferrin concentrations. The median
time that the Purdue-owned horses were under environmental challenge was 4 days (range 3–7 days; testing
was performed on the ﬁrst day of increased respiratory
eﬀorts), whereas the client-owned horses displayed
clinical signs of RAO exacerbation in their home environments for a median of 22 months (range,
3–129 months). The timing of transferrin measurement
reported in studies of humans has varied from 24 hours
to 5 years of environmental exposure.20,22 Transferrin
concentrations may change with the duration and severity of inﬂammation, and thus the discrepancy in results
between studies is not surprising.
Although we believe that RAO-aﬀected horses are
suitable models for humans with severe asthma, care
must be used when extrapolating data between species.
Equine RAO is a naturally occurring disease that shares
the asthmatic characteristics of airway inﬂammation,
airway obstruction, and airway hypersensitivity. The
pulmonary anatomy of horses is very similar to that of
humans. The genetic characteristics of RAO are also
quite complex, as is the genetic background of the
horses with the disease.24
One limitation to RAO in horses as a model for
asthma in humans is the primary inﬂammatory cell
involved in the diseases. In RAO, the neutrophil is the
primary pulmonary inﬂammatory cell, whereas the eosinophil is the major inﬂammatory cell in most forms of
mild allergic asthma. However, in severe acute asthma,

the neutrophil is more commonly associated with pulmonary inﬂammation.25 Keeping in mind the cytologic
characteristics of the 2 diseases, RAO may serve as a
valuable model for severe acute asthma and IAD as a
model for mild asthma.
One unexpected ﬁnding from this study was the large
number of client-owned horses that were presented with
no history of respiratory disease that in fact had IAD.
In addition, some horses with a presumptive diagnosis
of RAO actually had IAD. Most of the client-owned
horses evaluated in this study were older and retired
from high-level activity, which could lead to undetected
clinical signs of IAD (because it typically is associated
with impaired athletic performance). This ﬁnding highlights the necessity of identifying biomarkers to diﬀerentiate between RAO and IAD in the ﬁeld, otherwise only
pulmonary function testing in conjunction with BALF
cytology allows that diﬀerentiation. In addition, it is
likely that the incidence of IAD in older horse populations is under-represented because of the lack of owner
complaints of respiratory signs.
This study demonstrated that RAO-aﬀected horses
during exacerbation of clinical signs had lower secretoglobin and transferrin expression in their BALF than
did healthy control horses or horses with IAD. These
diﬀerences suggest that secretoglobin and transferrin
may be useful in the future as biomarkers or as possible
treatment targets for RAO.
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e
Human apo-transferrin, catalog # 3188-AT; R&D Systems, Minneapolis, MN
f
Sheep anti-horse transferrin, catalog # A70-110A; Bethyl Laboratories, Montgomery, TX
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Donkey anti-sheep IgG, catalog # 713-035-147; Jackson
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National Institutes of Health, Bethesda, MD
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